

DEPARTMENT OF JUSTICE**Antitrust Division****Notice Pursuant to the National Cooperative Research and Production Act of 1993—OBI Consortium, Inc.**

Notice is hereby given that, on June 15, 2000, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* ("the Act"), OBI Consortium, Inc. has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership status. The notifications were filed for the purpose of extending the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, bCandid Corporation, Boulder, CO; BEA Systems, San Jose, CA; Catalyst Capital, Newport Beach, CA; Consolidated Commerce, Des Plaines, IL; Ectone, Santa Clara, CA; ESSELTE Corporation, Greenwich, CT; iMedium, Wayne, PA; and Passport International, Ltd., Mt. Pleasant, SC have been added as parties to this venture.

No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and OBI Consortium, Inc. intends to file additional written notification disclosing all changes in membership.

On September 10, 1997, OBI Consortium, Inc. filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the **Federal Register** pursuant to Section 6(b) of the Act on November 10, 1997 (62 FR 60531).

The last notification was filed with the Department on March 3, 2000. A notice was published in the **Federal Register** pursuant to Section 6(b) of the Act on June 29, 2000 (65 FR 40131).

Constance K. Robinson,

Director of Operations Antitrust Division.

Joint Venture Worksheet

(Supplemental Filings Only)

- A. Name of venture: OBI Consortium, Inc.
Nature of notification: Supplemental Concise statement of purpose (if purpose has changed): Same as before—no changes.
- B. For ventures involving research and development only:
Identity of parties added to venture:
1. bCandid Corporation, Boulder, CO

2. BEA Systems, San Jose, CA
 3. Catalyst Capital, Newport Beach, CA
 4. Consolidated Commerce, Des Plaines, IL
 5. Ectone, Santa Clara, CA
 6. ESSELTE Corporation, Greenwich, CT
 7. iMedium, Wayne, PA
 8. Passport International, Ltd., Mt. Pleasant, SC
- Identity of parties dropped from venture:

- C. For ventures involving production:
Identity and nationality of parties to joint production venture:

[FR Doc. 00-19387 Filed 7-31-00; 8:45 am]

BILLING CODE 4410-11-M

DEPARTMENT OF JUSTICE**Drug Enforcement Administration****Importation of Controlled Substances; Notice of Application**

Pursuant to Section 1008 of the Controlled Substances Import and Export Act (21 U.S.C. 958(i)), the Attorney General shall, prior to issuing a registration under this Section to a bulk manufacturer of a controlled substance in Schedule I or II and prior to issuing a regulation under Section 1002(a) authorizing the importation of such a substance, provide manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing.

Therefore, in accordance with Section 1301.34 of Title 21, Code of Federal Regulations (CFR), notice is hereby given that on June 6, 2000, Chiragene, Inc., 7 Powder Horn Drive, Warren, New Jersey 07059, made application by renewal to the Drug Enforcement Administration to be registered as an importer of phenylacetone (8501), a basic class of controlled substance listed in Schedule II.

The firm plans to import the phenylacetone to manufacture amphetamine.

Any manufacturer holding, or applying for, registration as a bulk manufacturer of this basic class of controlled substance may file written comments on or objections to the application described above and may, at the same time, file a written request for a hearing on such application in accordance with 21 CFR 1301.43 in such form as prescribed by 21 CFR 1316.47.

Any such comments, objections, or requests for a hearing may be addressed, in quintuplicate, to the Deputy Assistance Administrator, Office of

Diversions Control, Drug Enforcement Administration, United States Department of Justice, Washington, D.C. 20537, Attention: DEA Federal Register Representative (CCR), and must be filed no later than (30 days from publication).

This procedure is to be conducted simultaneously with and independent of the procedures described in 21 CFR 1301.34(b), (c), (d), (e), and (f). As noted in a previous notice at 40 FR 43745-46 (September 23, 1975), all applicants for registration to import basic class of any controlled substance in Schedule I or II are and will continue to be required to demonstrate to the Deputy Assistant Administrator, Office of Diversions Control, Drug Enforcement Administration that the requirements for such registration pursuant to 21 U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR 1301.34(a), (b), (c), (d), (e), and (f) are satisfied.

Dated: July 11, 2000.

John H. King,

Deputy Assistant Administrator, Office of Division Control, Drug Enforcement Administration.

[FR Doc. 00-19290 Filed 7-31-00; 8:45 am]

BILLING CODE 4410-09-M

DEPARTMENT OF JUSTICE**Federal Bureau of Investigation****Agency Information Collection Activities: Proposed Collection; Comment Requested**

ACTION: Notice of information collection under review; Extension of a currently approved collection; Return A—Monthly Return of Offenses Known to the Police and Supplement to Return A—Monthly Offenses Known to the Police.

Office of Management and Budget (OMB) approval is being sought for the information collection listed below. This proposed information collection was previously published in the **Federal Register** on May 30, 2000, allowing for a 60-day public comment period.

The purpose of this notice is to allow an additional 30 days for public comment until August 31, 2000. This process is conducted in accordance with 5 CFR 1320.10. Written comments and/or suggestions regarding the item(s) contained in this notice, especially regarding the estimated public burden and associated response time, should be directed to the Office of Management